Results

1–10 of 69 results for Socioeconomics

The Impact of Good Days' Underfunding on Retinal Disease Management Insights From a National Survey of American Society of Retina Specialists Members
Michael M. Lai, MD, PhD
Annual Meeting Talks
2025
Comparative Facility Time-Based Financial Efficiency Coefficient Analysis of Retinal Surgery vs Cataract Surgery in Ambulatory Surgery Centers
Miguel A. Busquets, MD, FACS
Annual Meeting Talks
2025
Take Out the Trash: Environmental Burden Associated With Intravitreal Injections
Abdullah Abou-Samra, MD
Annual Meeting Talks
2025
Analysis of Antivascular Endothelial Growth Factor Utilization Trends and Prescriber Characteristics Based on Medicare Part B Claims Data: 2017-2022
Stephanie B Engelhard, MD
Annual Meeting Talks
2025
Retinal Procedure Volume and Inflation-Adjusted Medicare Reimbursement in the 21st Century
Ron A. Adelman, MD, MPH, MBA
Annual Meeting Talks
2025
Economic Impact of Anti-Vascular Endothelial Growth Factor Prior Authorization Process
Ella H Leung, MD
Annual Meeting Talks
2025
Evaluating the Visual, Anatomic, and Treatment Effects of Switching from Higher-cost Anti-VEGF to Lower-cost Bevacizumab After Loss of Copay Assistance (Good Days) Funding in Neovascular Age-Related Macular Degeneration
Jesse J Jung, MD, FASRS
Updates from the Field
2026
Impact of Loss of Good Days Copay Assistance Program on Clinical and Anatomical Outcomes of Retinal Disease
Danny A. Mammo, MD
Updates from the Field
2026
Biosimilar Paradox: How Biosimilar Use Will Increase Patient and Healthcare Costs
Ravi Parikh, MD MPH
Annual Meeting Talks
2023
Economic Benefit of Higher Durability Anti-VEGF Agents in the Treatment of Neovascular Macular Degeneration
Sabin Dang, MD
Annual Meeting Talks
2023